You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
Development of a Novel Whole Genome Sequencing-based Platform for Rapid Identification and Antimicrobial Profiling of Uropathogens
SBC: Day Zero Diagnostics, Inc. Topic: RComplicated urinary tract infections are severe or life-threatening infections that extend beyond a simple bladder infection and occur most frequently in hospitalized patients. There are over 2.8 million cases of complicated urinary tract infections in the U.S. each year, with 20% of cases progressing to urosepsis, leading to nearly 150,000 deaths each year. Effective management of complicated uri ...
SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Evaluation of the safety and efficacy of non-invasive sonodynamic therapy for diffuse intrinsic pontine glioma
SBC: SonalaSense Inc Topic: 102PROJECT SUMMARY Diffuse Intrinsic Pontine Gliomas (DIPG) are rare and deadly pediatric brain tumors. They are extremely aggressive tumors that are found in the pons, which controls many of the body's most vital functions such as breathing, blood pressure, and heart rate. There is no currently effective means of treatment for DIPG, and the median survival is 7-11 months after diagnosis. Thus, there ...
SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Parkin activators for cardioprotective therapies
SBC: Progenra, Inc Topic: NHLBIMyocardial infarction followed by left ventricular remodeling is the leading cause of heart failure (HF). Current therapies are inadequate to modulate adverse remodeling and prevent subsequent cardiac failures. As such there is a critical unmet need to identify new therapies. There is strong evidence suggesting that mitophagy exerts cardioprotective effects following infarction (MI) and that impai ...
SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Deep learning augmented protein mapping software to screen large compound libraries
SBC: ACPHARIS Topic: 400Fragment based drug discovery starts with screening libraries of fragment-sized organic molecules for binding to the target protein. The fragments cluster at binding hot spots, the most important regions for drug discovery, and can be extended into larger and higher affinity ligands. The protein-mapping program FTMap is a computational analogue of fragment screening experiments. Acpharis has licen ...
SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Enhancing the Engraftment of Microglia for the Treatment of Neurological Disease
SBC: Novoglia, Inc. Topic: NINDSThere are no effective treatments for microgliopathies, a class of neurodegenerative disorders that are caused by the absence or misfunction of specialized cells in the brain, called microglia. One potential strategy to treat patients with a microgliopathy is to replace their diseased microglia with new cells. The NovoGlia technology platform uses induced pluripotent stem cells to generate new mic ...
SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
PERSEVERE-PEF: optimizing medical therapy saves lives in heart failure with preserved ejection fraction
SBC: Optima Integrated Health Inc. Topic: NHLBINeed. In the US, heart failure (HF) is the contributing cause of 1 in 8 deaths. HF with preserved ejection fraction (HFpEF) affects close to 50% of all HF patients. The 5-years mortality is 35%. HFpEF multi-organ syndrome clinical care management is complex and time consuming. In addressing HFpEF, the American College of Cardiology guidelines directed medical therapy (GDMT) references the medical ...
SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
High-resolution genomic mapping of ssDNA and associated proteins for Alzheimer's disease research
SBC: Epicypher, Inc. Topic: NIAPROJECT SUMMARYEpiCypher is collaborating with Dr. Jessica Tyler (an expert in aging, DNA repair and epigenetics), to develop CUTandRUssNTM (Cleavage Under Targets and Release Using single-stranded Nuclease), a first-in-class single-stranded DNA (ssDNA) mapping technology for research into the early pathogenesis of and possible interventions for Alzheimer’s Disease (AD). The double-stranded conf ...
SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Quantifying microstructural changes in Alzheimer's disease using Restriction Spectrum Imaging
SBC: Cortechs Labs, Inc. Topic: NIAProject Summary/Abstract The overall goal of this project is to deliver an automated diffusion image analysis tool to be used in a clinical setting that quickly evaluates the diffusion images in conjunction with MR volumetric images and reports diffusion-based microstructural parameters derived from segmented anatomical locations to determine Alzheimer’s disease status of patients. Alzheimer’s ...
SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Targeting inflammation and oxidative stress to treat acute lung injury with CNP-miR146a
SBC: CERIA THERAPEUTICS, INC. Topic: NHLBIPROJECT SUMMARY - Acute respiratory distress syndrome (ARDS) accounts for 10% of ICU admissions worldwide with a mortality as high as 46%. This incidence has risen dramatically in the last year due to the novel coronavirus (SARS-CoV-2) causing COVID-19, and ARDS is the leading cause of death in COVID-19 patients. In the United States, COVID-19 has infected over 30 million and killed 550,000 people ...
SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Engineered super-affinity reagents for detection of histone post-translational modifications
SBC: Epicypher, Inc. Topic: 400PROJECT SUMMARYHistone post-translational modifications (PTMs) are widely studied due to their diverse roles in controlling gene expression. The study of PTMs largely relies on antibodies; however, we have shown that the majority of commercial histone PTM antibodies are plagued by low efficiency and/or low specificity. Antibody quality is of special concern for ultra-low cell input approaches, whi ...
SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health